An observational study in Cardiac Imaging, Cardiac Imaging Techniques and Lymphoma, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Hodgkin Disease with a site in Italy — 11 open to participants now, 17 under way, 3 of them phase 3. Hodgkin Disease · Italy.
Among the 98 studies in Hodgkin Disease with a site in Italy, this one is the 8th largest by planned enrollment of the 24 observational ones that give a count, is one of 6 that started in 2024, is one of 24 observational ones, reaches primary completion later than 15 of the 16 other live ones, and was the 94th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →11 of the 98 studies in Hodgkin Disease with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Italiana Linfomi - ETS · Sites in Italy
Ages 18+
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18–38 · Women only
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
Fondazione Italiana Linfomi - ETS · Sites in Italy
Ages 65+
AstraZeneca · Sites in Italy, United States, Australia and 8 more countries
Ages 12+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 45 · Phase 3 17
First in 1989; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 123 across 161 observational studies indexed under Hodgkin Disease.
Median enrollment 106 across the 72 interventional studies, 139 across the 24 observational. Of the 67 that completed or were terminated, 24 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 98 have an industry lead sponsor. The 10 most frequent:
IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 514 studies on the registry; 289 are open to participants now.
IRCCS Azienda Ospedaliero-Universitaria di Bologna has 5 studies filed under Hodgkin Disease — fewer than ten, so there is no comparison to draw.
5 of the studies in Hodgkin Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06822855Azienda USL Reggio Emilia - IRCCSChanging Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma | 2026-12 |
| NCT05300282Fondazione Italiana Linfomi - ETSStudy of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients | 2026-12-15 |
| NCT06733987IRCCS Azienda Ospedaliero-Universitaria di BolognaImmunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma | 2027-02-01 |
| NCT03407144Merck Sharp & Dohme LLCSafety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | 2027-02-12 |
| NCT03131531A.O. Ospedale Papa Giovanni XXIIIBergamo Lymphoid Cancer Registry | 2027-03-23 |
Add all 5 to your calendar (.ics) → With an account.
Among the 98 studies in Hodgkin Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the diagnostic capability of Spectral CT (performed with contrast agent as part of routine oncological follow-up) in detecting signs of acute and chronic early-onset cardiac toxicity from anthracyclines in patients with Hodgkin's lymphoma and diffuse large B-cell lymphoma undergoing treatment regimens that include a drug from this family.
To evaluate the diagnostic capability of Spectral CT, performed with contrast agent during routine oncological follow-ups, in detecting signs of acute and chronic early-onset cardiac toxicity caused by anthracyclines in patients with Hodgkin's lymphoma and diffuse large B-cell lymphoma undergoing treatment regimens including anthracycline-based drugs. Spectral CT provides advanced data, such as iodine maps and tissue characterization, allowing for the identification and quantification of hyperemia, edema, and fibrosis. These findings are particularly promising in cardiovascular imaging, where tissue characterization and early detection of myocardial damage (edema or fibrosis) are traditionally achieved with cardiac MRI (cardio-MRI).
In clinical oncology, anthracyclines improve survival rates but are associated with cardiotoxic effects, classified as acute (up to two weeks after therapy), early chronic (within one year), or late chronic (years or decades later), often irreversible. Anthracycline-related cardiac toxicity is dose-dependent and varies from subclinical alterations to overt symptoms such as arrhythmias, fibrosis, and heart failure. Early detection of myocardial damage with imaging techniques is critical for initiating cardioprotective therapy, which can significantly improve cardiac outcomes.
Currently, functional imaging modalities like echocardiography and cardio-MRI are used. While echocardiography offers functional data such as LVEF and strain, cardio-MRI provides more precise and reproducible measurements and structural data (e.g., edema via T2 mapping and fibrosis via late gadolinium enhancement, LGE). Structural markers, such as positive LGE and elevated T1 mapping or ECV values, are highly sensitive and can detect damage before functional decline, enabling earlier intervention. However, cardio-MRI has limitations, such as long acquisition times, high costs, and contraindications like claustrophobia.
With the introduction of Spectral CT, studies have shown that advanced CT scanners can also visualize and quantify myocardial fibrosis (as late-iodine enhancement, LIE) and measure ECV, comparable to cardio-MRI. This suggests that Spectral CT could become a "one-stop-shop" modality, capable of assessing both the patient's primary disease and signs of anthracycline-induced cardiotoxicity through post-processing of the same images, even in subclinical stages.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
This study's planned enrollment of 160 is above the median of 123 across 161 observational studies indexed under Hodgkin Disease.
Browse Hodgkin Disease studies →IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 514 studies on the registry; 289 are open to participants now.
Compared within Hodgkin Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients diagnosed with Hodgkin's lymphoma and diffuse large B-cell lymphoma (DLBCL) undergoing treatment regimens including anthracyclines will participate in the study. They will be enrolled and undergo CT and MRI follow-ups conducted by the cardiac radiology team.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Myocardial damage
Diagnosis of the presence of acute myocardial damage (hyperemia present) or chronic damage (hyperemia absent) based on the evaluation of the following parameters obtained from Spectral CT: * Increased ECV (ECV value above the upper limit of normality, set at 30%). * Presence of Late Iodine Enhancement (LIE) in the myocardium (areas of myocardial hyperdensity due to late-phase iodine contrast accumulation) and its relative extent. * Presence of Hyperemia or Hypoperfusion using the Spectral "Iodine No Water" parameter (visual scoring of hyper- or hypodense areas; consideration of a possible quantitative score in mgI/ml). * Diagnosis of myocardial damage due to chemotherapy (CHT) based on clinical practice upon hospital discharge.
Time frame: 36 months after starting CHT
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Aug 2029, 66 months after the start.
Of 58 non-industry observational studies under Hodgkin Disease, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 149. This study's planned 66 months is close to that.
Counting every sponsor, half of 65 studies reached it within 61 months; a quarter within 34 and three quarters within 149.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna →